Creative Biolabs is a global company that focuses on antibody development. With extensive experience and advanced platforms, we can provide a series of AI-augmented antibody discovery services for research, diagnostics, and therapeutics. Now we offer a unique way to find rare antibody clusters by augmenting our screening services with an AI-powered antibody drug discovery platform.
Artificial intelligence (AI) technologies have also been widely used in antibody design based on big data and machine learning. In addition, the biophysical features of candidate antibodies, such as stability, solubility, chemical properties can be evaluated and optimized by different types of AI models to reduce the cost and improve the therapeutic efficiency.
Creative Biolabs combines state-of-the-art artificial intelligence, big data, and phage display techniques to discover rare antibodies and expand antibody diversity. At Creative Biolabs, the growing number of biophysical data for various antibody targets has been integrated into the machine learning (ML) algorithms to predict antibodies that bind to a given antigen target with high affinity. The submitted antibody sequences maximize the antibodies’ therapeutic potential while minimizing safety and manufacturing risks. AI technology can also evaluate and optimize the safety, binding affinity, solution viscosity, solubility, as well as pharmacokinetics of specific antibodies.
Antigen: biotinylated Avi-tagged BG505 gp140 trimer containing a redesigned HR1 bend
Data generation: Ion Torrent PGM sequencing; NGS of homo sapien: diverse antibody phage library
Creative Biolabs is recognized as the world leader for providing the most diverse portfolio of AI-augmented drug discovery solutions for worldwide customers. We are proud to partner with our clients on the journey of bringing novel antibody candidates to market. If you are interested in our services, please feel free to contact us for closer communication.
Follow us on:
Copyright © 2023 Creative Biolabs. All Rights Reserved.